Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology

Journal of Pharmaceutical and Biomedical Analysis

Volumn 67-68, Issue , 2012, Pages 148-153

  Giorgi, M ^a   Meizler, A ^b   Mills, P C ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Canine plasma; HPLC; Opioid; Quantification; Tapentadol

Indexed keywords

ACETIC ACID; ACETONITRILE; ALCOHOL; O NORTRAMADOL; TAPENTADOL; TRAMADOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; EXCITATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; JUGULAR VEIN; JUGULAR VENIPUNCTURE; LIMIT OF QUANTITATION; LIQUID PHASE MICROEXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRESSURE GRADIENT; PRIORITY JOURNAL; REACTION TIME; SPECTRAL SENSITIVITY; SPECTROFLUOROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS; VEIN PUNCTURE;

ANALGESICS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; MALE; PHENOLS; SPECTROMETRY, FLUORESCENCE;

EID: 84862131403     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.04.020     Document Type: Article

References (28)

1. Kress H.G. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?. Eur. J. Pain 2010, 14:781-783.
2. Tzschentke T.M., Jahnel U., Kogel B., Christoph T., Englberger W., De Vry J., Schiene K., Okamoto A., Upmalis D., Weber H., Lange C., Stegmann J.U., Kleinert R. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 2009, 45:483-496.
3. Hartrick C.T., Rozek R.J. Tapentadol in pain management: a (opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011, 25:359-370.
4. Buynak R., Shapiro D.Y., Okamoto A., Van Hove I., Rauschkolb C., Steup A., Lange B., Lange C., Etropolski M. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin. Pharmacother. 2010, 11:1787-1804.
5. Wild J.E., Grond S., Kuperwasser B., Gilbert J., McCann B., Lange B., Steup A., Häufel T., Etropolski M.S., Rauschkolb C., Lange R. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010, 10:416-427.
6. Afilalo M., Etropolski M.S., Kuperwasser B., Kelly K., Okamoto A., Van Hove I., Steup A., Lange B., Rauschkolb C., Haeussler J. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin. Drug Invest. 2010, 30:489-505.
7. Stegmann J.U., Weber H., Steup A., Okamoto A., Upmalis D., Daniels S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr. Med. Res. Opin. 2008, 24:3185-3196.
8. Daniels S., Casson E., Stegmann J.U., Oh C., Okamoto A., Rauschkolb C., Upmalis D. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr. Med. Res. Opin. 2009, 25:1551-1561.
9. Daniels S.E., Upmalis D., Okamoto A., Lange C., Häeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr. Med. Res. Opin. 2009, 25:765-776.
10. Hartrick C., Van Hove I., Stegmann J.U., Oh C., Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin. Ther. 2009, 31:260-271.
11. Kleinert R., Lange C., Steup A., Black P., Goldberg J., Desjardins P. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth. Analg. 2008, 107:2048-2055.
12. Giorgi M., Soldani G., Manera C., Ferrarini P., Sgorbini M., Saccomanni G. Pharmacokinetics of tramadol and its metabolites m1, m2 and m5 in horses following intravenous immediate release (fasted/fed) and sustained release single dose administration,. J. Equine Vet. Sci. 2007, 27:481-488.
13. Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Turini V., Kowalski C. Biopharmaceutical profile of tramadol in the dog. Vet. Res. Commun. 2009, 33S1:189-192.
14. Giorgi M., Saccomanni G., Del Carlo S., Andreoni V. Pharmacokinetic of tramadol and its major metabolites after intravenous and intramuscular injections in alpacas (Vicugna pacos). J. Camel Pract. Res. 2010, 17:123-126.
15. Dhanjal J.K., Wilson D.V., Robinson E., Tobin T.T., Dirokulu L. Intravenous tramadol: effects: nociceptive properties, and pharmacokinetics in horses. Vet. Anaesth. Analg. 2009, 36:581-590.
16. Souza M.J., Cox S.K. Tramadol use in zoologic medicine. Vet. Clin. North Am. Exot. Anim. Pract. 2011, 14:117-130.
17. Giorgi M. Tramadol vs tapentadol: a new horizon in pain treatment?. Am. J. Anim. Vet. Sci. 2012, 7:7-11.
18. Coulter C., Taruc M., Tuyay J., Moore C. Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection. J. Anal. Toxicol. 2010, 34:458-463.
19. ®) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2010, 34:450-457.
20. Han Z., Liu X., Ren Y., Luan L., Wu Y. A rapid method with ultra-high-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of five type B trichothecenes in traditional Chinese medicines. J. Sep. Sci. 2010, 33:1923-1932.
21. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York. 2nd edn.
22. de Sousa A.B., Santos A.C., Schramm S.G., Porta V., Górniak S.L., Florio J.C., de Souza Spinosa H. Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. J. Vet. Pharmacol. Ther. 2008, 31:45-51.
23. De Leo M., Giorgi M., Saccomanni G., Manera C., Braca A. Evaluation of tramadol and its main metabolites in horse plasma by high-performance liquid chromatography/fluorescence and liquid chromatography/electrospray ionization tandem mass spectrometry techniques. Rapid Commun. Mass Spectrom. 2009, 23:228-236.
24. Terlinden R., Ossig J., Fliegert F., Goehler K. Pharmacokinetics Excretion and Metabolism of Tapentadol HCl a Novel Centrally Acting Analgesic in Healthy Subjects 2007, Abstract American Academy of Pain Medicine, New Orleans, LA, February, Abs 689, p. S26.
25. Smit J.W., Oh C., Rengelshausen J., Terlinden R., Ravenstijn P.G., Wang S.S., Upmalis D., Mangold B. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotheraphy 2010, 30:25-34.
26. Anonymous Guidelines for Validation of Analytical Procedures: Methodology - International Conference of Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use 1996.
27. Giorgi M., Meizler A., Mills P.C. Pharmacokinetics of the novel atypical opioid tapentadol after oral and intravenous administration in dogs. Vet. J. 2012.
28. Terlinden R., Ossig J., Fliegert F., Lange C., Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 2007, 32:163-169.